Obviousness-type double patenting ("ODP") is a judicially created doctrine that seeks to prevent patent owners from extending patent protection beyond the statutorily afforded term. This webinar will explore the evolving provenance of obviousness-type double patenting in addressing the following topics:
- Traditional confines of the doctrine
- Federal Circuit expansion in Sun Pharma and Gilead
- Retrenchment in Breckenridge Pharma and Ezra Ventures
- Future prospects.
The Evolving Provenance of Obviousness-type Double Patenting
Live MBHB Webinar
When/Where:
Tuesday, March 19, 2019 8:00 am Pacific Daylight Time (San Francisco, GMT-07:00)
11:00 am Eastern Daylight Time (New York, GMT-04:00)
Duration:
1 hour 15 minutes
Speakers:
MBHB partner(s) Kevin Noonan, Ph.D. and Sarah Fendrick, Ph.D.
Cost:While there is no fee to participate, all attendees must register in advance and, in order to receive MCLE credit, must participate online and individually. Register online here
Credit:
MCLE credit is pending for the states of California, Illinois, New Jersey,* New York,* North Carolina and Virginia (*via reciprocity). For other states, check your credit-granting authority.
By:
McDonnell Boehnen Hulbert & Berghoff LLP is committed to educating clients and friends of the firm with respect to significant developments and trends in the areas of intellectual property law.
More Information:
www.mbhb.com/events/
No comments:
Post a Comment